In the next 4 years, it is expected to submit 14 potential blockbuster new drug listing applications. Johnson & Johnson presents its R&D blueprint

On the 20th, the executives of Johnson & Johnson introduced the company's pharmaceutical R&D strategy and key projects in detail at the investor meeting

Image source: Johnson & Johnson's official website

CAR-T therapy that is expected to become the standard treatment for advanced multiple myeloma

Carvykti (cilta-cel), a CAR-T therapy targeting B cell maturation antigen (BCMA) jointly developed by Janssen and Legend Bio, has been granted priority review by the US FDA and is expected to be approved next spring

Image source: Johnson & Johnson's official website

Precision therapy to revolutionize lung cancer treatment

Rybrevant, a bispecific antibody targeting EGFR and MET, has received accelerated approval from the U.

It has also obtained positive results in the treatment of NSCLC patients with skipping mutations in exon 14 of the MET gene

▲Introduction to Rybrevant (picture source: Johnson & Johnson's official website)

Currently, Rybrevant is used in combination with the third-generation EGFR inhibitor lazertinib developed by Johnson & Johnson, and is being used in multiple clinical trials to treat NSCLC patients with common EGFR mutations

Image source: Johnson & Johnson's official website

Innovative therapies that have the potential to treat more than a dozen rare and common diseases

Autoimmune diseases caused by autoantibodies attacking human proteins, cells and tissues include rare diseases such as myasthenia gravis, hemolytic diseases of the fetus and newborns, and common diseases such as rheumatoid arthritis

Nipocalimab binds to FcRn, so that the autoantibodies taken up by monocytes and endothelial cells will not be released into the blood again, but will be degraded in the cells.

▲Introduction to Nipocalimab (picture source: Johnson & Johnson's official website)

In a phase 2 clinical trial for the treatment of myasthenia gravis (a rare disease in which autoantibodies block nerve synaptic signaling), nipocalimab was treated for two weeks and a significant response was observed in patients

▲Phase 2 clinical trial results of Nipocalimab in the treatment of patients with myasthenia gravis (picture source: Johnson & Johnson's official website)

Johnson & Johnson plans to explore the therapeutic effects of nipocalimab in a variety of autoimmune diseases.

Image source: Johnson & Johnson's official website

Gene therapy for the treatment of eye diseases

Johnson & Johnson reached a research and development cooperation agreement with MeiraGTx in 2019 to jointly develop gene therapies for a series of inherited retinal diseases

▲AAV-RPGR obtained positive Phase 1/2 clinical trial results (Image source: Johnson & Johnson's official website)

A new generation of oral anticoagulants

Milvexian, jointly developed by Johnson & Johnson and Bristol-Myers Squibb, is a new generation of oral coagulation factor XIa inhibitor

▲Milvexian did not increase the risk of bleeding while reducing venous thromboembolism (Image source: Johnson & Johnson official website)

Innovative treatment for refractory hypertension

Aprocitentan, jointly developed by Johnson & Johnson and Idorsia, is a potential "first-in-class" dual endothelin receptor antagonist

▲Aprocitentan's Phase 2 clinical trial results (picture source: Johnson & Johnson official website)

In addition, the adult respiratory syncytial virus (RSV) vaccine of Johnson & Johnson recently reached the primary and key secondary endpoints in a phase 2b clinical trial in elderly people over 65 years old, and its effectiveness in preventing lower respiratory diseases was 80%

Johnson & Johnson also predicts that the company will submit about 36 regulatory applications for extended product indications in the next four years

[1] JOHNSON & JOHNSON PHARMACEUTICAL BUSINESS REVIEW 2021.

[2] As J&J moves to split its business, execs lay out future R&D focus — and tout megablockbuster potential.